test

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions

Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) | Childhood Supratentorial Primitive Neuroectodermal Tumor | Ewing Sarcoma of Bone | Extraosseous Ewing Sarcoma | Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Peripheral Primitive Neuroectodermal Tumor of the Kidney | Soft Tissue | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor

Trial Phase

Phase III

Trial Purpose and Description

Trial Purpose

This randomized phase III trial is studying combination chemotherapy in treating patients with non-metastatic extracranial Ewing sarcoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.


Participation Guidelines

Age:
Up to 50 Years
Gender:
Both

Eligibility Criteria

Inclusion Criteria:

  • Newly diagnosed extracranial, non-metastatic Ewing sarcoma or primitive neuroectodermal tumors of bone or soft tissue
  • For the purpose of this study, any of the following are considered localized disease:
  • Chest wall tumors with ipsilateral pleural effusions
  • Ipsilateral positive pleural fluid cytology
  • pleural-based secondary tumor nodules
  • Regional node involvement, based on clinical suspicion confirmed by pathologic documentation, are considered to be non-metastatic disease
  • Tumors arising in the bony skull (extra-dural) are considered to be extracranial
  • No evidence of metastatic disease, including the following:
  • Lesions that are discontinuous from the primary tumor, are not regional lymph nodes, and do not share a body cavity with the primary tumor
  • Contralateral pleural effusion and contralateral pleural nodules
  • Distant lymph node involvement
  • Pulmonary nodules that meet the following criteria:
  • Solitary nodule &gt 0.5 cm or multiple nodules of &gt 0.3 cm unless biopsied and negative for Ewing sarcoma
  • Biopsies of solitary nodule &lt 0.5 cm or multiple nodules &lt 3.0 cm (are not required but if performed) positive for metastatic disease
  • No tumors arising in the intra-dural soft tissue
  • Creatinine clearance or radioisotope GFR = 70 mL/min OR serum creatinine based on age
    and/or gender as follows:
  • 0.4 mg/dL (1 month to &lt 6 months of age)
  • 0.5 mg/dL (6 months to &lt 1 year of age)
  • 0.6 mg/dL (1 year to &lt 2 years of age)
  • 0.8 mg/dL (2 years to &lt 6 years of age)
  • 1.0 mg/dL (6 years to &lt 10 years of age)
  • 1.2 mg/dL (10 years to &lt 13 years of age)
  • 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 years to &lt 16 years of age)
  • 1.7 mg/dL (male) or 1.4 mg/dL (female) (= 16 years of age)
  • Total bilirubin &lt 1.5 times upper limit of normal (ULN)
  • AST or ALT &lt 2.5 times ULN
  • Shortening fraction of = 27% by echocardiogram OR ejection fraction = 50% by
    radionuclide angiogram
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception for the duration of study treatment
  • No prior chemotherapy or radiotherapy
  • Prior biopsy of the primary tumor without an attempt at complete or partial resection allowed
  • Patients are still allowed if unplanned excision was attempted or accomplished as long as adequate imaging was obtained prior to surgery
  • No other concurrent chemotherapy or immunomodulating agents (including steroids unless used as an antiemetic)
  • No concurrent sargramostim (GM-CSF)
Sponsor:
Children's Oncology Group (The)
National Cancer Institute (NCI)
Dates:
02/02/2011
Last Updated:
Study HIC#:
1101007854